Where Will G1 Therapeutics Inc (GTHX) Stock Go Next After It Is Higher By 17.24% in a Week?

G1 Therapeutics Inc (GTHX) stock has risen 17.24% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

G1 Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on GTHX!

See Full GTHX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With GTHX Stock Today?

G1 Therapeutics Inc (GTHX) stock is trading at $1.70 as of 12:44 PM on Monday, Nov 20, a gain of $0.13, or 7.96% from the previous closing price of $1.57. The stock has traded between $1.57 and $1.90 so far today. Volume today is more active than usual. So far 914,374 shares have traded compared to average volume of 590,417 shares. To screen for more stocks like G1 Therapeutics Inc click here.

More About G1 Therapeutics Inc

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies. Click Here to get the full Stock Report for G1 Therapeutics Inc stock.